Ignite Creation Date:
2024-05-05 @ 4:58 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00354094
Status:
TERMINATED
Last Update Posted:
2007-11-08
First Post:
2006-07-18
Brief Title:
SS-Reboxetine Long Term Safety Study In Post-Shingles Pain
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A Phase 2B Long-Term Randomized Open-Label Safety And Tolerability Trial Comparing SS-Reboxetine PNU-165442g With Routine Care In Patients With Postherpetic Neuralgia PHN
Status:
TERMINATED
Status Verified Date:
2007-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
The study was stopped due to businessoperational issues
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the long term up to 2 years safety and tolerability of SS-Reboxetine in patients with pain after shingles
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None